| (1) |
Glinoer D, Hesch D, Lagasse R, Laurberg P. 1987
The management of hyperthyroidism due to Graves' disease in Europe 1986.
Results of an international survey. Acta Endocrinol (Copenh). 285(Suppl):
5-23. |
| (2) |
Solomon B, Glinoer D, Lagasse R, Wartofsky L.
1990 Current trends in the management of Graves' disease. J Clin Endocrinol
Metab. 70: 1518-1524. |
| (3) |
Wartofsky L, Glinoer D, Solomon B. Lagasse R.
1991 Differences and similarities in the treatment of diffuse goiter in
Europe and the United States. Exp Clin Endocrinol. 97: 243-251. |
| (4) |
Ford HC, Delahunt JW. Feek CM. 1991 The management
of Graves' disease in New Zealand: results of a national survey. NZ Med
J. 104: 251-252. |
| (5) |
Nagayama Y, Izumi M, Nagataki S. 1989 The management
of hyperthyroidism due to Graves' disease in Japan in 1988. The Japan Thyroid
Association. Endocrinol Jpn. 36: 299-314. |
| (6) |
Tunbridge WMG, Evered DC, Hall R, et al. 1977
The spectrum of thyroid disease in a community: the Whickham survey. Clin
Endocrinol (Oxf). 7: 481-493. |
| (7) |
Petersen K, Lindstedt G, Lundberg P-A, Bengtsson
C, Lapidus L, Nystrom E. 1991 Thyroid disease in middle-aged and elderly
Swedish women: thyroid related hormones, thyroid dysfunction and goitre
in relation to age and smoking. J Intern Med. 229: 407-414. |
| (8) |
Tallstedt L, Lundell G, T6ning O. et al. 1991
Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism.
N Engl J Med. 326: 1733-1738. |
| (9) |
Larsson L-G. 1955 Studies on radioiodine treatment
of thyrotoxicosis: with special reference to the behavior of the radioiodine
tracer tests. Acta Radiol. 126(Suppl): 1-164. |
| (10) |
Davies TF, Yeo PPB, Evered DC, Clark F, Rees Smith
B, Hall R. 1977 Value of thyroid-stimulating-antibody determinations
in predicting short-term thyrotoxic relapse in Graves' disease. Lancet.
1: 1181-1182. |
| (11) |
McGregor AM, Rees Smith B. Hall R, Petersen MM, Miller
M, Dewar PJ. 1980 Prediction of relapse in hyperthyroid Graves' disease.
Lancet. 1: 1101-1103. |
| (12) |
Teng CS, Yeung RTT. 1980 Changes in thyroid-stimulating
antibody activity in Graves' disease treated with antithyroid drug and its
relationship to relapse: a prospective study. J Clin Endocrinol Metab. 50:
144-147. |
| (13) |
Hardisty CA, Hanford L, Munro DS. 1981 The prediction
of relapse after drug treatment of Graves' disease by assay of long acting
thyroid stimulator-protector (LATS-P). Clin Endocrinol (Oxf). 14: 509-517. |
| (14) |
Madec AM, Laurent MC, Lorcy Y, et al. 1984 Thyroid
stimulating antibodies: an aid to the strategy of treatment of Graves' disease?
Clin Endocrinol (Oxf). 21: 247-255. |
| (15) |
T6tterman TH, Karlsson FA, Bengtsson M, Mendel-Hartvig
I. 1987 Induction of circulating activated suppressor-like T cells by
methimazole therapy for Graves's disease. N Engl J Med. 316: 15-22. |
| (16) |
Orgiazzi J. 1987 Management of Graves' hyperthyroidism.
Endocrinol Metab Clin North Am. 16: 365-388. |
| (17) |
Allannic H, Fauchet R, Orgiazzi J. et al. 1990
Antithyroid drugs and Graves' disease: a prospective randomized evaluation
of the efficacy of treatment duration. J Clin Endocrinol Metab. 70: 675-69. |
| (18) |
Tamai H, Nakagawa T, Fukino O, et al. 1980 Thionamide
therapy in Graves' disease: relation of relapse to duration of therapy.
Ann Intern Med. 92: 488-490. |
| (19) |
Romaldini JH, Bromberg N, Werner RS, et al. 1983
Comparison of effects of high and low dosage regimens of antithyroid drugs
in the management of Graves' hyperthyroidism. J Clin Endocrinol Metab. 57:
563-570. |
| (20) |
Reinwein D, Benker G, Lazarus JH, Alexander WD, European
Multicenter Study Group on Antithyroid Drug Treatment. 1993 A prospective
randomized trial of antithyroid drug dose in Graves' disease therapy. J
Clin Endocrinol Metab. 76: 1516. |
| (21) |
Berglund J, Christensen SB, Dymling JF, Hallengren
B. 1991 The incidence of recurrence and hypothyroidism following treatment
with antithyroid drugs, surgery or radioiodine in all patients with thyrotoxicosis
in Malmo during the period 1970-1974. J Intern Med. 229: 435-442. |
| (22) |
Winsa B, Dahlberg A. Jansson R, Agren H, Karlsson
FA. 1990 Factors influencing the outcome of thyrostatic drug therapy
in Graves' disease. Acta Endocrinol (Copenh). 122: 722-728. |
| (23) |
Mori Y, Matoba N, Miura S, Sakai S, Taira Y.
1992 Clinical course and thyroid stimulating hormone (TSH) receptor antibodies
during surgical treatment of Graves' disease. World J Surg. 16: 647-653. |
| (24) |
Okamoto T, Fujimoto Y, Obara T, Ito Y, Aiba M.
1992 Retrospective analysis of prognostic factors affecting the thyroid
function status after subtotal thyroidectomy for Graves' disease. World
J Surg. 16: 690-696. |
| (25) |
Menegaux F. Ruprecht T. Chigot J-P. 1993 The
surgical treatment of Graves' disease. Surg Gynecol Obstet. 176: 277-282. |
| (26) |
Sugrue D, McEvoy M, Feely J. Drury MI. 1980 Hyperthyroidism
in the land of Graves-results of treatment by surgery, radioiodine and carbimazole
in 837 cases. Q J Med. 49: 51-61. |
| (27) |
Roher H-D, Horster FA, Frilling A, Goretzki PE, Witte
J. 1991 Surgery for immunogenic hyperthyroidism. Exp Clin Endocrinol.
97: 292-296. |
| (28) |
Andaker L. Johansson K, Smeds S, Lennquist S.
1992 Surgery for hyperthyroidism: hemithyroidectomy plus contralateral resection
or bilateral resection? A prospective randomized study of postoperative
complications and long-term results. World J Surg. 16: 765-769. |
| (29) |
Tallstedt L, Lundell G, Blomgren H. Bring J.
1994 Does early administration of thyroxine reduce the development of Graves'
ophthalmopathy after radio-iodine treatrnent? Eur J Endocrinol. 130: 494-497. |
| (30) |
Nofal MM, Beierwaltes WH, Patno ME. 1966 Treatment
of hyperthyroidism with sodium iodide I-131. JAMA. 197: 605-610. |
| (31) |
Douglas JG. 1973 The Vanderbilt experience with
I-131 treatment for Graves' disease. South Med J. 66: 92-94. |
| (32) |
Holm L-E, Lundell G, Israelsson A, Dahlqvist I.
1982 Incidence of hypothyroidism occurring long after iodine-131 therapy
for hyperthyroidism. J Nucl Med. 23: 103-107. |
| (33) |
Holm L-E. 1982 Changing annual incidence of hypothyroidism after
iodine-131 therapy for hyperthyroidism, 1951-1975. J Nucl Med. 23: 108-112. |
| (34) |
Sridama V, McCormick M, Kaplan EL, Fauchet R, DeGroot
LJ. 1984 Long-terrn follow-up study of compensated low-dose 131-I therapy
for Graves' disease. N Engl J Med. 311: 426-432. |
| (35) |
Glennon JA, Gordon ES, Sawin CT. 1972 Hypothyroidism after low-dose
131-I treatment of hyperthyroidism. Ann Intern Med. 76: 721-723. |
| (36) |
McGregor AM, Petersen MM, Capiferri R, Evered DC,
Rees Smith B, Hall R. 1979 Effects of radioiodine on thyrotropin binding
inhibiting immunoglobulins in Graves' disease. Clin Endocrinol (Oxf). 11:
437-444. |
| (37) |
Hardisty CA, Fowles A. Munro DS. 1984 The effect of radioiodine
and antithyroid drugs on serum long acting thyroid stimulator protector
(LATS-P). A three year prospective study. Clin Endocrinol (Oxf). 20: 597-605. |
| (38) |
Bech K, Nistrup Madsen S. 1980 Influence of treatment
with radioiodine and propylthiouracil on thyroid stimulating immunoglobulins
in Graves' disease. Clin Endocrinol (Oxf). 13: 417-424. |
| (39) |
Gamstedt A. Wadman B, Karlsson A. 1986 Methimazole, but not betamethasone,
prevents 131-I treatment-induced rises in thyrotropin receptor autoantibodies
in hyperthyroid Graves' disease. J Clin Endocrinol Metab. 62: 773-777. |
| (40) |
Almqvist S, Algyere P. 1972 Hypothyroidism in
progressive ophthalmopathy in Graves' disease. Acta Ophthalmol (Copenh).
50: 761-770. |
| (41) |
Karlsson FA. Dahlberg PA, Jansson R, Westermark K, Enoksson P.
1989 Importance of TSH receptor activation in the development of severe
endocrine ophthalmopathy. Acta Endocrinol (Copenh). 121(Suppl 2): 132-141. |
| (42) |
Sj6berg HE. Saaf M, Bostrbm L. Lundell G. Tallstedt
L. 1989 Observations on progress periods in Graves' ophthalmopathy.
Acta Endocrinol (Copenh). 121(Suppl 2): 179-181. |